News articles about TG Therapeutics (NASDAQ:TGTX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. TG Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.3888978594844 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Short Interest in TG Therapeutics Inc (TGTX) Declines By 15.0% (americanbankingnews.com)
- TG Therapeutics (TGTX) Posts Earnings Results, Hits Estimates (americanbankingnews.com)
- TG Therapeutics (TGTX) PT Raised to $27.00 (americanbankingnews.com)
- TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017 Financial Results and Business Update (finance.yahoo.com)
- TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update (finance.yahoo.com)
Shares of TG Therapeutics (TGTX) opened at $16.45 on Tuesday. TG Therapeutics has a 1 year low of $7.25 and a 1 year high of $17.35. The company has a market cap of $1,160.00, a price-to-earnings ratio of -8.57 and a beta of 1.40.
A number of research firms have recently weighed in on TGTX. BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, January 11th. ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Raymond James Financial reissued a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, December 12th. Zacks Investment Research raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 16th. Finally, B. Riley reissued a “buy” rating and issued a $27.00 price target (up previously from $21.50) on shares of TG Therapeutics in a research note on Friday. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $24.60.
In related news, CFO Sean A. Power sold 32,006 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the sale, the chief financial officer now owns 517,464 shares in the company, valued at approximately $4,398,444. The transaction was disclosed in a filing with the SEC, which is available through this link. 16.70% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact TG Therapeutics (TGTX) Stock Price” was posted by BBNS and is the property of of BBNS. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://baseballnewssource.com/2018/03/13/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-tg-therapeutics-tgtx-stock-price/2022598.html.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.